


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bruce D. C. hen et al.	CONFIRMATION NO. 1445
		FILING DATE January 4, 2002	GROUP 1642



UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Lap	6,146,629	11/14/2000	Dagan, et al.	424	149.1	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
WD	WO 96/33735	10/31/1996	PCT	A61K	39/00		X
WD	WO 00/56772	09/28/2000	PCT	C07K	16/24		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
WD	Li, S.-L. et al., "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth," <i>Cancer Immunology and Immunotherapy</i> , 49:243-252 (2000).
WD	Hermanto, U. et al., "Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation," <i>Cell Growth & Differentiation</i> , 11:655-664 (2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bruce D. C hen t al.	CONFIRMATION NO. 1445
		FILING DATE January 4, 2002	GROUP 1642

*O I P E JCSP
01/01/2002*


UNITED STATES. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JAA	4,399,216	08/16/83	Axel et al.	435	6	
1	4,510,245	04/09/85	Cousens et al.	435	172.3	
	4,634,665	01/06/87	Axel et al.	435	68	
	4,740,461	04/26/88	Kaufman	435	68	
	4,912,040	03/27/90	Kaufman et al.	435	69.6	
	4,959,455	09/25/90	Clark et al.	530	351	
	4,968,516	11/06/90	Koszinowki et al.	435	172.3	
	5,151,510	09/29/92	Stec et al.	536	27	
	5,168,062	12/01/92	Stinski	435	240.2	
	5,179,017	01/12/93	Axel et al.	435	240.2	
	5,223,409	06/29/93	Ladner et al.	435	69.7	
	5,530,101	06/25/96	Queen et al.	530	387.3	
	5,545,806	08/13/96	Lonberg et al.	800	2	
	5,545,807	08/13/96	Surani et al.	800	2	
	5,585,089	12/17/96	Queen et al.	424	133.1	
	5,587,458	12/24/96	King et al.	530	387.3	
	5,591,669	01/07/97	Krimpenfort et al.	800	2	
	5,612,205	03/18/97	Kay et al.	435	172.3	
	5,625,126	04/29/97	Lonberg et al.	800	2	
	5,625,825	04/29/97	Rostoker et al.	395	730	
	5,633,425	05/27/97	Lonberg et al.	800	2	
	5,643,763	07/01/97	Dunn et al.	435	91.1	
	5,661,016	08/26/97	Lonberg et al.	435	172.3	
	5,693,761	12/02/97	Queen et al.	536	23.53	
	5,693,792	12/02/97	Torii et al.	540	358	
✓	5,714,350	02/03/98	Co et al.	435	69.6	
LAA	5,721,367	02/24/98	Kay et al.	800	2	

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruc D. C hen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JP	5,741,957	04/21/98	Deboer et al.	800	2	
	5,747,498	05/05/98	Schnur et al.	514	259	
	5,750,172	05/12/98	Meade et al.	426	580	
	5,756,687	05/26/98	Denman et al.	530	412	
	5,770,429	06/23/98	Lonberg et al.	435	240.2	
	5,777,085	07/07/98	Co et al.	530	388.23	
	5,789,215	08/04/98	Berns et al.	435	172.3	
	5,789,650	08/04/98	Lonberg et al.	800	2	
	5,792,783	08/11/98	Tang et al.	514	397	
	5,814,318	09/29/98	Lonberg et al.	424	184.1	
	5,827,690	10/27/98	Meade et al.	435	69.6	
	5,834,504	11/10/98	Tang et al.	514	418	
	5,861,510	01/19/99	Piscopio et al.	544	131	
	5,863,949	01/26/99	Robinson et al.	514	575	
	5,877,305	03/02/99	Huston et al.	536	23.53	
	5,883,113	03/16/99	Tang et al.	514	418	
	5,886,020	03/23/99	Tang et al.	514	418	
	5,886,152	03/23/99	Nakatani et al.	530	387.3	
	5,916,771	06/29/99	Hori et al.	435	69.6	
	5,939,598	08/17/99	Kucherlapati et al.	800	25	
	5,985,615	11/16/99	Jakobovits et al.	435	69.6	
	5,994,619	11/30/99	Stice et al.	800	2	
	5,998,209	12/07/99	Jokobovits et al.	435	463	
	6,054,297	04/25/00	Carter et al.	435	69.6	
	6,075,181	06/13/00	Kucherlapati et al.	800	25	
Y	6,091,001	07/18/00	Jakobovits et al.	800	18	
LP	6,114,598	09/05/00	Kucherlapati et al.	800	18	

EXAMINER

DATE CONSIDERED

1/29/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LH	6,130,364	10/10/00	Jakobovits et al.	4800	6	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
LH	0 216 846	04/08/87	EPO	C12N	15/00		
	0 256 055	02/24/88	EPO	C12N	15/52		
	0 323 997	07/19/89	EPO	C12N	15/12		
	0 338 841	10/25/89	EPO	C12N	15/00		
	0 606 046	07/13/94	EPO	C07D	213/42		
	0 780 386	06/25/97	EPO	C07D	309/08		
	0 818 442	01/14/98	EPO	C07C	317/44		
	0 931 788	07/28/99	EPO	C07C	311/03		
	1 004 578	05/31/00	EPO	C07D	207/28		
	WO 90/05719	05/31/90	PCT	C07C	323/62		
	WO 91/10741	07/25/91	PCT	C12P	21/06		
	WO 91/17271	11/14/91	PCT	C12Q	1/70		
	WO 92/01047	01/23/92	PCT	C12N	15/00		
	WO 92/02190	02/20/92	PCT	A61C	7/00		
	WO 92/09690	06/11/92	PCT	C12N	15/00		
	WO 92/15679	09/17/92	PCT	C12N	15/10		
LH	WO 92/18619	10/29/92	PCT	C12N	7/01		
LH	WO 92/20791	11/26/92	PCT	C12N	15/00		

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/01288	01/21/93	PCT	C12N	15/13		
	WO 93/06213	04/01/93	PCT	C12N	15/00		
	WO 94/02602	02/03/94	PCT	C12N	15/00		
	WO 95/19970	07/27/95	PCT	C07D	239/70		
	WO 95/21613	08/17/95	PCT	A16K	31/24		
	WO 96/27583	09/12/96	PCT	C07C	31/29		
	WO 96/33172	10/24/96	PCT	C07D	211/96		
	WO 96/33735	10/31/96	PCT	A61K	39/00		
	WO 96/34096	10/31/96	PCT	C12N	15/00		
	WO 97/13760	04/17/97	PCT	C07D	239/70		
	WO 97/22596	06/26/97	PCT	C07D	239/94		
	WO 97/32856	09/12/97	PCT	C07D	239/94		
	WO 98/02434	01/22/98	PCT	C07D	405/04		
	WO 98/02437	01/22/98	PCT	C07D	471/04		
	WO 98/02438	01/22/98	PCT	C07D	471/04		
	WO 98/03516	01/29/98	PCT	C07F	9/30		
	WO 98/07697	02/26/98	PCT	C07D	211/58		
	WO 98/14451	04/09/98	PCT	C07D	487/04		
	WO 98/16654	04/23/98	PCT	C12P	21/00		
	WO 98/24893	06/11/98	PCT	C12N	15/00		
	WO 98/30566	07/16/98	PCT	C07D	493/08		

EXAMINER

DATE CONSIDERED 11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruc D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
10	WO 98/33768	08/06/98	PCT	C07C	311/29		
	WO 98/34915	08/13/98	PCT	C07C	317/44		
	WO 98/34918	08/13/98	PCT	C07D	211/62		
	WO 98/50356	11/12/98	PCT	C07D	207/09		
	WO 98/50433	11/12/98	PCT	C07K	16/00		
	WO 98/54093	12/03/98	PCT	C01D	293/72		
	WO 99/07675	02/18/99	PCT	C07C	311/29		
	WO 99/10349	03/04/99	PCT	C07D	487/04		
	WO 99/16755	04/08/99	PCT	C07D	235/08		
	WO 99/24440	05/20/99	PCT	C07D	495/04		
	WO 99/29667	06/17/99	PCT	C07D	211/16		
	WO 99/35132	07/15/99	PCT	C07D	239/94		
	WO 99/35146	07/15/99	PCT	C07D	471/04		
	WO 99/45031	09/10/99	PCT	C07K	16/28		
	WO 99/52889	10/21/99	PCT	C07D	309/14		
	WO 99/52910	10/21/99	PCT	C07D	493/08		
	WO 99/53049	10/21/99	PCT	C12N	15/10		
	WO 99/61422	12/02/99	PCT	C07D	209/04		
	WO 99/62890	12/09/99	PCT	C07D	275/03		
10	WO 00/09560	02/24/00	PCT	C07K	16/00		
10	WO 00/37504	06/29/00	PCT	C07K	16/28		

EXAMINER

DATE CONSIDERED

11/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
LJH	Altschul et al., "Basic local alignment search tool," <i>Journal of Molecular Biology</i> , 215(1):403-410 (1990)
	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , 25(17):3389-402 (1997)
	Arteaga et al., "Interference of the IGF system as a strategy to inhibit breast cancer growth," <i>Breast Cancer Research Treatment</i> , 22:101-106 (1992)
	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <i>Journal of Clinical Investigation</i> , 84:1418-1423 (1989)
	Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," <i>PNAS</i> , 88:7978-7982 (1991)
	Barkan, "New options for diagnosing and treating acromegaly," <i>Cleveland Clinic Journal of Medicine</i> , 65(7):343-349 (1998)
	Bayes-Genis et al., "The insulin-like growth factor axis. A review of atherosclerosis and restenosis," <i>Circulation Research</i> , 86(2):125-130 (2000)
	Bird et al., "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-426 (1988)
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)
	Butler et al., "Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression," <i>Cancer Research</i> , 58:3021-3027 (1998)
	Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," <i>Journal of Molecular Biology</i> , 196:901-917 (1987)
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)
RM	Clackson et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)

EXAMINER

DATE CONSIDERED

11/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not compliant and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 <i>O I P E</i> OCT 07 2004 U.S. PATENT AND TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
		APPLICANT Bruce D. Cohen et al.	CONFIRMATION NO. 1445
		FILING DATE January 4, 2002	GROUP 1642

<i>20</i>	Cullen et al., "Insulin-like growth factor receptor expression and function in human breast cancer," <i>Cancer Research</i> , 50: 48-53 (1990)
<i>21</i>	Cullen et al., "Glutathione S-transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors," <i>Cancer Research</i> , 63: 8097-8102 (2003)
	D'Ambrosio et al., "A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells <i>in vivo</i> and inhibits tumorigenesis, <i>Cancer Research</i> , 56:4013-4020 (1996)
	DiGiovanni et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <i>PNAS</i> , 97(7):3455-3460 (2000)
	Drexhage et al., "Endocrine autoimmune diseases," <i>Netherlands Journal of Medicine</i> , 45:285-293 (1994)
	Du Pasquier, "Evolution of the immune system," <i>Fundamental Immunology, Second Edition</i> , edited by William E. Paul, Raven Press Ltd., NY, 139-165 (1989)
	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>Journal of Medicinal Chemistry</i> , 30:1229-1239 (1987)
	Fagerstam et al., "Detection of antigen-antibody interactions by surface plasmon resonance. Applications to epitope mapping," <i>Journal of Molecular Recognition</i> , 3:(5,6):208-214 (1990)
	Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunomethods</i> , 4:72-81 (1994)
	Fauchere, "Elements for the rational drug design of peptides drugs," <i>Advances in Drug Research</i> , 15:29-69 (1986)
	Foekens et al., "Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer," <i>Cancer Research</i> , 49:7002-7009 (1989)
<i>22</i>	Freed et al., "Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture," <i>Journal of Molecular Endocrinology</i> , 3:183-189 (1989)
<i>23</i>	Fuchs et al., "Targeting recombinant antibodies to the surface of <i>Escherichia coli</i> : fusion to a peptidoglycan associated lipoprotein," <i>Biotechnology</i> , 9:1369-1372 (1991)
<i>24</i>	Galfre et al., "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

	Garrad et al., "F _{AB} assembly and enrichment in a monovalent phage display system," <i>Biotechnology</i> , 9:1373-1377 (1991)
	Geran, et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems," <i>Cancer Chemotherapy Reports</i> , 3(2):1-104 (1972)
	Goldring et al., "Cytokines and cell growth control," <i>Critical Reviews in Eukaryotic Gene Expression</i> , 1:31-326 (1991)
	Gonnet et al., "Exhaustive matching of the entire protein sequence database," <i>Science</i> , 256:1443-1445 (1992)
	Gram et al., "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library," <i>PNAS</i> , 89:3576-3580 (1992)
	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)
	Green et al., "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>Journal of Experimental Medicine</i> , 188(3):483-495 (1998)
	Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," <i>The EMBO Journal</i> , 12(2):725-734 (1993)
	Grimberg et al., "Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis," <i>Journal of Cellular Physiology</i> , 183:1-9 (2000)
	Guo et al., "Characterization of insulinlike growth factor I receptors in human colon cancer," <i>Gastroenterology</i> , 102(4):1101-1108 (1992)
	Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines," <i>The EMBO Journal</i> , 13(14):3286-3295 (1994)
	Hawkins et al., "Selection of phage antibodies by binding affinity mimicking affinity maturation," <i>Journal of Molecular Biology</i> , 226:889-896 (1992)
	Hay et al., "Bacteriophage cloning and <i>Escherichia coli</i> expression of a human IgM Fab," <i>Hum. Antibod. Hybridomas</i> , 3:81-85 (1992)
	Hockenberry et al., "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death," <i>Nature</i> , 348:334-336 (1990)

EXAMINER

DATE CONSIDERED



11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
APPLICANT Bruc D. C hen et al.	CONFIRMATION NO. 1445
FILING DATE January 4, 2002	GROUP 1642


	Holliger et al., "Diabodies: small bivalent and bispecific antibody fragments," <i>PNAS</i> , 90:6444-6448 (1993)
	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Research</i> , 19(15):4133-4137 (1991)
	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," <i>Science</i> , 246:1275-1281 (1989)
	Huston et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>PNAS</i> , 85:5879-5883 (1988)
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10(8): 949-957 (1997)
	Jiang et al., "Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor," <i>Oncogene</i> , 18:6071-6077 (1999)
	Johnsson et al., "Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies," <i>Journal of Molecular Recognition</i> , 8:125-131 (1995)
	Johnsson et al., "Immobilization of proteins to a carboxymethyl dextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors," <i>Analytical Biochemistry</i> , 198:268-277 (1991)
	Jonsson et al., "Introducing a biosensor based technology for real-time biospecific interaction analysis," <i>Ann. Biologie Clinique</i> , 51:19-26 (1993)
	Jonsson et al., "Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology," <i>BioTechniques</i> , 11(5):620-627 (1991)
	Kaiser et al., "Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer," <i>Journal of Cancer Research and Clinical Oncology</i> , 119(11):665-668 (1993)
	Kalebic et al., "In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34 ^{cdc2} ," <i>Cancer Research</i> , 54:5531-5534 (1994)

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
APPLICANT Bruce D. C hen t al.	CONFIRMATION NO. 1445
FILING DATE January 4, 2002	GROUP 1642


LN	Kim et al., "Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling," <i>Journal of Biological Chemistry</i> , 273:34543-34550 (1998)
	Lane, "A death in the life of p53," <i>Nature</i> , 362:786-787 (1993)
	LaPlanche et al., "Phosphorothiolate-modified oligodeoxyribonucleotides, III. NMR and UV spectroscopic studies of the R _p -R _p , S _p -S _p , and R _p -S _p duplexes, [d(GG ₅ AATTCC)] ₂ , derived from diastereomeric O-ethyl phosphorothioates," <i>Nucleic Acids Research</i> , 14(22):9081-9093 (1986)
	Laron, "Clinical use of somatomedin-1," <i>Pediatric Drugs</i> , 1(3):155-159 (1999)
	LeRoith et al., "Molecular and cellular aspects of the insulin-like growth factor I receptor," <i>Endocrine Reviews</i> , 16(2):143-163 (1995)
	Li et al., "Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain," <i>Journal of Biological Chemistry</i> , 269:32558-32564 (1994)
	Macaulay, "Insulin-like growth factors and cancer," <i>British Journal of Cancer</i> , 65:311-320 (1992)
	Macaulay et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <i>Cancer Research</i> , 50:2511-2517 (1990)
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13(22): 5303-5309 (1994)
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> , 348:552-554 (1990)
	McDonnell et al., "bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation," <i>Cell</i> , 57:79-88 (1989)
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)
VA	Moody et al., "Growth factor and peptide receptors in small cell lung cancer," <i>Life Sciences</i> , 52:1161-1173 (1993)
VA	Moyer et al., "Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase," <i>Cancer Research</i> , 57:4838-4848 (1997)

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not confirmed and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. C. hen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

<i>h</i>	Nakanishi et al., "Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro," <i>Journal of Clinical Investigation</i> , 82:354-359 (1988)
<i>h</i>	Pearson, "Empirical statistical estimates for sequence similarity searches," <i>Journal of Molecular Biology</i> , 276:71-84 (1998)
<i>h</i>	Pearson, "Rapid and sensitive sequence comparison with FASTP and FASTA," <i>Methods in Enzymology</i> , 183:63-98 (1990)
<i>h</i>	Pearson, "Flexible sequence similarity searching with the FASTA3 program package," <i>Methods in Molecular Biology</i> , 132:185-219 (2000)
<i>h</i>	Pearson, "Using the FASTA program to search protein and DNA sequence databases," <i>Methods in Molecular Biology</i> , 24:307-331 (1994)
<i>h</i>	Pearson, "Effective protein sequence comparison," <i>Methods in Enzymology</i> , 266:227-258 (1996)
<i>h</i>	Pietrzkowski et al., "Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors," <i>Cell Growth & Differentiation</i> , 3:199-205 (1992)
<i>h</i>	Pietrzkowski et al., "Roles of insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells," <i>Molecular and Cellular Biology</i> , 12(9):3883-3889 (1992)
<i>h</i>	Poljak, "Production and structure of diabodies," <i>Structure</i> , 2:1121-1123 (1994)
<i>h</i>	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 291(2):739-748 (1999)
<i>h</i>	Pollak et al., "Presence of somatomedin receptors on primary human breast and colon carcinomas," <i>Cancer Letters</i> , 38:223-230 (1987)
<i>h</i>	Prager et al., "Dominant negative inhibition of tumorigensis <i>in vivo</i> by human insulin-like growth factor I receptor mutant," <i>PNAS</i> , 91:2181-2185 (1994)
<i>h</i>	Remacle-Bonnet et al., "Expression of Type I, but not Type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line," <i>Journal of Clinical Endocrinology and Metabolism</i> , 75(2):609-616 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. C. Chen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

100	Resnicoff et al., "The insulin-like growth factor I receptor protects tumor cells from Apoptosis <i>in vivo</i> ," <i>Cancer Research</i> , 55:2463-2469 (1995)
1	Resnicoff et al., "Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors," <i>Cancer Research</i> , 55:3739-3741 (1995)
	Rizo et al., "Constrained peptides: models of bioactive peptides and protein substructures," <i>Annual Review of Biochemistry</i> , 61:387-418 (1992)
	Rodriguez-Tarduchy et al., "Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells," <i>Journal of Immunology</i> , 149(2):535-540 (1992)
	Rosen et al., "Circulating IGF-I: new perspectives for a new century," <i>Trends in Endocrinology and Metabolism</i> , 10(4):136-141 (1999)
	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <i>Cancer Research</i> , 53:2475-2478 (1993)
	Sell et al., "Insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis," <i>Cancer Research</i> , 55:303-306 (1995)
	Smith et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," <i>Nature Medicine</i> , 5(12): 1390-1395 (1999)
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>Journal of the American Chemical Society</i> , 106(20):6077-6079 (1984)
	Stein et al., "Physiochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucleic Acids Research</i> , 16(8):3209-3221 (1988)
	Tappy et al., "Antibodies to insulin-like growth factor 1 receptors in diabetes and other disorders," <i>Diabetes</i> , 37:1708-1714 (1988)
W	Thompson et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <i>Pediatric Research</i> , 32(4):455-459 (1988)
	Thornton et al., "Prediction of progress at last," <i>Nature</i> , 354(14):105-106 (1991)
W	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>The EMBO Journal</i> , 10(12):3655-3659 (1991)

EXAMINER

DATE CONSIDERED 1/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF2	APPLN. NO. 10/038,591
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Bruce D. C hen et al.	CONFIRMATION NO. 1445
		FILING DATE January 4, 2002	GROUP 1642

	Traunecker et al., "Janusin: new molecular design for bispecific reagents," <i>International Journal of Cancer</i> , 7:51-52 (1992)
	Trojan et al., "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA," <i>Science</i> , 259:94-97 (1993)
	Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," <i>Chemical Reviews</i> , 90(4):543-584 (1990)
	Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," <i>Cell</i> , 61:203-212 (1990)
	Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity," <i>The EMBO Journal</i> , 5(10):2503-2512 (1986)
	Veber et al., "The design of metabolically-stable peptide analogs," <i>TINS</i> , 8(9):392-396 (1985)
	Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
	Weightman et al., "Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy," <i>Autoimmunity</i> , 16:251-257 (1993)
	Williams, "Programmed cell death: apoptosis and oncogenesis," <i>Cell</i> , 65:1097-1098 (1991)
	Winter et al., "Humanized antibodies," <i>Immunology Today</i> , 14(6):243-246 (1993)
	Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <i>Nature Biotechnology</i> , 18:521-526 (2000)
	Wright et al., "Genetically engineered antibodies: progress and prospects," <i>Critical Reviews in Immunology</i> , 12:(3,4)125-168 (1992)
	Yee et al., "Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer," <i>Molecular Endocrinology</i> , 3(3):509-517 (1989)
	Yee et al., "Insulin-like growth factor II mRNA expression in human breast cancer," <i>Cancer Research</i> , 48:6691-6696 (1988)
	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not compliance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.
ABX-PF2

APPLN. NO.
10/038,591

APPLICANT
Bruce D. Cohen et al.

**CONFIRMATION
NO. 1445**

FILING DATE
January 4, 2002

**GROUP
1642**

1409

Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991)

EXAMINER



DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conflict with MPEP 609; Draw line through citation if not conflict and not considered. Include copy of this form with next communication to applicant.